BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 27554419)

  • 1. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
    Dhiman G; Lohia N; Jain S; Baranwal M
    Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.
    Kashyap M; Jaiswal V; Farooq U
    Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach.
    Adhikari UK; Rahman MM
    Infect Genet Evol; 2017 Dec; 56():75-91. PubMed ID: 29107145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
    Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
    Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Conserved Peptides Comprising Multiple T Cell Epitopes of Matrix 1 Protein in H1N1 Influenza Virus.
    Lohia N; Baranwal M
    Viral Immunol; 2015 Dec; 28(10):570-9. PubMed ID: 26398199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
    Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
    Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.
    Derouazi M; Di Berardino-Besson W; Belnoue E; Hoepner S; Walther R; Benkhoucha M; Teta P; Dufour Y; Yacoub Maroun C; Salazar AM; Martinvalet D; Dietrich PY; Walker PR
    Cancer Res; 2015 Aug; 75(15):3020-31. PubMed ID: 26116496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting promiscuous antigenic T cell epitopes of Mycobacterium tuberculosis mymA operon proteins binding to MHC Class I and Class II molecules.
    Saraav I; Pandey K; Sharma M; Singh S; Dutta P; Bhardwaj A; Sharma S
    Infect Genet Evol; 2016 Oct; 44():182-189. PubMed ID: 27389362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape and selection of vaccine epitopes in SARS-CoV-2.
    Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
    Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic, Unbiased Mapping of CD8
    Stryhn A; Kongsgaard M; Rasmussen M; Harndahl MN; Østerbye T; Bassi MR; Thybo S; Gabriel M; Hansen MB; Nielsen M; Christensen JP; Randrup Thomsen A; Buus S
    Front Immunol; 2020; 11():1836. PubMed ID: 32983097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.
    Zhao W; Sher X
    PLoS Comput Biol; 2018 Nov; 14(11):e1006457. PubMed ID: 30408041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.